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Signaling via the intrinsic (mitochondrial) pathway of apoptosis represents one of the
critical signal transduction cascades that control the regulation of cell death. This
pathway is typically altered in human cancers, thereby providing a suitable target for
therapeutic intervention. Members of the Bcl-2 family of proteins as well as cell survival
signaling cascades such as the PI3K/Akt/mTOR pathway are involved in the regulation
of mitochondria-mediated apoptosis. Therefore, further insights into the molecular
mechanisms that form the basis for the control of mitochondria-mediated apoptosis will
likely open new perspectives to bypass evasion of apoptosis and treatment resistance in
human cancers.
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INTRODUCTION
Programmed cell death is an ancient, evolutionary highly con-
served program that exists in every cell to execute cell death upon
appropriate stimulation (Lockshin and Zakeri, 2007). Evasion
of cell death is a hallmark of human cancers and contributes
to tumorigenesis, tumor progression and treatment resistance
(Fulda, 2009; Hanahan and Weinberg, 2011) .A p o p t o s i si so n eo f
the best characterized forms of programmed cell death that plays
animportantroleinvariousphysiologicalandpathophysiological
circumstances (Lockshin and Zakeri, 2007). The mitochondrial
pathway of apoptosis, one of the two key apoptosis signaling
pathways, is initiated by a large variety of upstream stimuli and
tightly regulated by various factors including pro- and antiapop-
totic proteins of the Bcl-2 family as well as the phosphatidyli-
nositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) pathway (Engelman, 2009; Fulda et al., 2010). The
PI3K/Akt/mTOR signaling cascade belongs to the critical survival
programs that are typically overactivated in human cancers and
can promote cell survival by inhibiting the mitochondrial path-
way of apoptosis (Parcellier et al., 2008). The PI3K signaling net-
work diversiﬁes into many distinct downstream branches, one of
which leadsto the activation of mTOR (Shaw and Cantley, 2006).
In addition,intricate interactions between distinct kinase survival
networks have been described. Since small-molecule inhibitors
that block PI3K/Akt/mTOR signaling are currently undergoing
clinical evaluation in early trials, there is much interest to under-
stand how these inhibitors interfere with intracellular signaling
pathways, for example mitochondria-mediated apoptosis.
SIGNAL TRANSDUCTION OF APOPTOSIS
While a largevariety of intracellular signaling pathways and regu-
latorymolecules havebeenshown to impingeonthe regulationof
apoptotic programs, two major signaling cascades have emerged
that represent the core machinery of apoptosis. This includes the
extrinsic (cell receptor) pathway as well as the intrinsic (mito-
chondrial) pathway of apoptosis (Fulda and Debatin, 2006). The
intrinsic (mitochondrial) apoptosis pathway is centrally inte-
grated into a network of signal transduction cascades and is
responsivetoamultitudeofupstreamactivators. Amongtheseare
cell survival pathways such PI3K/Akt/mTOR signaling, proapop-
totic proteins of the Bcl-2 family, cellular stress stimuli, metabolic
alterations, hypoxic conditions, or increased levels of second
messenger molecules (Fulda et al., 2010). Within the mitochon-
drial pathway of apoptosis, the permeabilization of the outer
membrane of mitochondria constitutes a key event to con-
trol downstream signal transduction pathways. Mitochondrial
outer membrane permeabilization is associated with the release
of mitochondrial proteins from the intermembrane space into
the cytosol. This accounts for cytochrome c, second mitochon-
drial activator of caspases (Smac) and apoptosis-inducing fac-
tor (AIF). Cytochrome c promotes the aggregation of caspase-9
together with Apaf-1 in the cytosol to form a multi-protein
complex, i.e., the apoptosome that results in caspase-9 activa-
tion. The release of Smac from the mitochondrial interspace
into the cytosol promotes apoptosis by binding to IAP proteins,
thereby preventing IAP protein-mediated inhibition of caspases,
including caspase-3, -7, and -9 (Fulda and Vucic, 2012). AIF
translocates to the nucleus to trigger large-scale DNA fragmen-
tation in a caspase-independent manner (Hangen et al., 2010).
Given the fact that permeabilization of mitochondrial outer
membranes constitutes a central event with a profound impact
on cellular survival, this process is tightly regulated. Pro- and
antiapoptotic members of the Bcl-2 family localize to mito-
chondrial membranes and are involved in the control of mito-
chondrial outer membrane permeabilization (Adams and Cory,
2007).
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FIGURE 1 | Scheme of PI3K/Akt/mTOR-imposed antiapoptotic
signaling at the mitochondria. See text for details.
SURVIVAL SIGNALING VIA PI3K/Akt/mTOR
The PI3K/Akt/mTOR pathway represents a key signal transduc-
tion pathway that mediates cell growth and blocks cell death
(Shaw and Cantley, 2006). Aberrantly high activation of this
survival cascade is a characteristic feature of a large variety of
human malignancies and has been associated with carcinogene-
sis, tumor progression, treatment resistance, and poor prognosis
(Engelman, 2009). Ligation of growth factor receptors by their
corresponding growth factors typically results in the engage-
ment of this survival cascade in order to activate intracellular
programs that support proliferation and survival. Triggering of
growth factor receptors results in the phosphorylation of these
receptor tyrosine kinases that reside within the plasma mem-
brane. This, in turn, engages activation of the whole cascade
via PI3K and Akt activation. Positive output of this signaling is
antagonized by the tumor suppressorgene phosphatase and tensin
homologue deleted on chromosome 10 (PTEN), which acts as both
a lipid and a protein phosphatase (Yin and Shen, 2008). PTEN
can dephosphorylate PIP3, thereby shutting off PI3K/Akt signal
transduction.
Akt-IMPOSED ANTIAPOPTOTIC PROGRAMS IN CANCER
Among its various functions, Akt acts as an antiapoptotic factor
that directly or indirectly antagonizes cell death signal trans-
duction, for example via the mitochondrial pathway (Shaw and
Cantley, 2006). Akt has been reported to directly interfere with
cell death pathways by phosphorylating key apoptosis-regulatory
proteins which, in turn, results in a shift within the ratio of
pro- and antiapoptotic proteins toward the inhibition of cell
death (Figure1). One mechanism of how Akt interferes with
apoptosis signaling resides in Akt-mediated phosphorylation of
proapoptotic proteins which, in turn, results in inhibition of
their function. This mechanism accounts for Akt-mediated inhi-
bition of Bad, Omi/high temperature requirement protein A2
(HtrA2), caspase-9, and acinus (Parcellier et al., 2008). In addi-
tion, the multi-domain Bcl-2 protein Bax has been shown to
be phosphorylated in an Akt-dependent manner at its serine
residue at position 184 (Yamaguchi and Wang, 2001; Gardai
et al., 2004). This Akt-mediated phosphorylation of Bax leads
to a change in the conformation of Bax and blocks its activa-
tion. Besides Bax, also the Bcl-2 family protein Bim is phos-
phorylated at a serine residue, i.e., Ser 87 (Qi et al., 2006).
Akt-stimulated phosphorylationofBimpromotes its degradation
via the proteasome, thereby counteracting apoptosis induction.
While the phosphorylation of the proapoptotic Bcl-2 proteins
Bax and Bim reduces their proapoptotic potential, Akt-mediated
phosphorylation of some antiapoptotic factors, such as XIAP
and Mcl-1, vice versa decreases their antiapoptotic properties
by decreasing their protein stability. Accordingly, phosphoryla-
tion of XIAP and Mcl-1 by Akt enhances the degradation of
these proteins via the proteasomal machinery, resulting in a
reduction of XIAP and Mcl-1 protein expression (Dan et al.,
2004; Maurer et al., 2006). Apart from the direct interference
of Akt with cell death signaling pathways via phosphoryla-
tion of key signal transduction molecules, Akt has also been
reported to interfere with cell death programs indirectly via
the phosphorylation of transcription factors. This mechanism
applies to the transcription factors NF-κB and cAMP response
element-binding (CREB) protein as well as forkhead transcrip-
tion factors such as FOXO1, FOXO3a, FOXO4, and FOXO6.
Akt-stimulatedphosphorylationofthesetranscriptionfactorscan
on one side promote the expression of antiapoptotic proteins,
while on the other side it results in reduced expression levels
of proapoptotic proteins. For example, Akt-mediated activation
of the transcription factor NF-κB can lead to transactivation
of a wide range of antiapoptotic NF-κB target genes, including
Inhibitor of Apoptosis (IAP) proteins, Bcl-XL,a n dB c l - 2 ,j u s t
to name a few (Ozes et al., 1999; Romashkova and Makarov,
1999). By comparison, Akt-stimulated increase in the phospho-
rylation status of forkhead transcription factors shuts off their
transcriptional activity by sequestering these transcription fac-
tors in the cytosol. This, in turn, results in reduced expression
of proapoptotic proteins that are known to be regulated by fork-
head transcription factors, including Bim, Noxa, tumor necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL), and
FAS ligand (Van Der Heide et al., 2004). In addition, forkhead
transcription factors are involved in the control of ROS levels
via transcriptional regulation of antioxidant enzymes (de Keizer
et al., 2011).
SHIFTING THE RATIO OF ANTIAPOPTOTIC TOWARD
PROAPOPTOTIC FACTORS BY INHIBITION OF
PI3K/Akt/mTOR SIGNALING
Since PI3K/Akt/mTOR signaling represents a key regulatory
mechanism to control the activity of pro- and antiapoptotic
Bcl-2 family proteins, small-molecule inhibitors of this signal-
ing cascade open new perspectives to modulate the signaling
outcome of the mitochondrial pathwayofapoptosis. Accordingly,
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small-molecule inhibitors of PI3K/Akt/mTOR signaling have
been reported to tilt the balance between pro- and antiapop-
totic proteins toward apoptosis by decreasing the expression of
Mcl-1 and by increasing phosphorylation of BimEL resulting in
increased expression of BimEL (Bender et al., 2011; Opel et al.,
2011). Furthermore, enhanced activation of the transcription
factor FKHRL1 upon treatment with PI3K inhibitors caused
increased expression levels of NOXA, as NOXA is transcription-
ally activated by FKHRL1 (Obexer et al., 2007). Also, NOXA
expression levels are transcriptionally controlled by Hippo/Mst1
(Valis et al., 2011). Increased expression of NOXA may promote
mitochondrial apoptosis via at least two mechanisms. NOXA can
directly bind to Mcl-1 thereby antagonizing the antiapoptotic
functionofMcl-1(Ploneretal.,2008).Inaddition,Noxacancon-
tribute to downregulationofMcl-1bystimulating itsdegradation
via the proteasome (Ploner et al., 2008).
Downregulation of Mcl-1 levels upon treatment with
inhibitors of PI3K/Akt/mTOR signaling may involve posttran-
scriptional as well as transcriptional mechanisms. For example,
activation of GSK3β upon inhibition of PI3K/Akt/mTOR sig-
naling favors downregulation of Mcl-1 proteins, since GSK3β
promotes the proteasomal degradation of Mcl-1 by phos-
phorylation of its serine residue at position 159 (Maurer
et al., 2006). In addition, Mcl-1 is transcriptionally regulated
by PI3K/Akt/mTOR signaling (Kuo et al., 2001). In addition
to NOXA and Mcl-1, BimEL represents another Bcl-2 pro-
tein that is tightly regulated at the transcriptional level via
PI3K/Akt/mTOR signaling. The transcription factor FKHRL1,
which is turned off by aberrant PI3K/Akt/mTOR signaling,
transactivates the expression of BimEL,p r o v i d i n gam o l e c u l a r
explanation of how inhibitors of PI3K/Akt/mTOR signaling can
transcriptionally activate BimEL (Dijkers et al., 2000). In addi-
tion to this transcriptional level of regulation, BimEL is also
directly controlled by Akt-mediated phosphorylation at serine
residue 87 (Qi et al., 2006). This phosphorylation event stim-
ulates the degradation of BimEL via the proteasome (Qi et al.,
2006). Since BimEL can stimulate activation of Bax and Bak
both directly as well as indirectly by binding to antiapoptotic
Bcl-2, Bcl-XL, and Mcl-1, changes in Bim expression levels
upon inhibition of PI3K/Akt/mTOR signaling may constitute a
key event in the regulation of the mitochondrial pathway of
apoptosis.
Together, a number of recent studies have provided the molec-
ular basis for the observation that small-molecule inhibitors of
PI3K/Akt/mTOR signaling represent a potent strategy to enhance
the sensitivity of cancer cells toward cell death induction via
the mitochondrial pathway of apoptosis. Accordingly, small-
molecule inhibitors of PI3K/mTOR were shown to chemosen-
sitize various cancers to a large variety of anticancer drugs,
e.g., topoisomerase-1 or -2 inhibitors, platinum compounds,
or microtubule interfering agents (Wallin et al., 2010; Bender
et al., 2011; Kim et al., 2011; Mueller et al., 2012). This
PI3K/mTOR-mediated chemosensitization may involve a shifted
ratio between pro- and antiapoptotic Bcl-2 proteins, thereby
engaging mitochondrial outer membrane permeabilization and
the mitochondrial pathway of apoptosis. Overexpression of Bcl-
2 antagonized this PI3K/mTOR inhibitor-stimulated activation
of Bax and permeabilization of mitochondrial outer membrane
and profoundly rescued cell death induction following treat-
ment with chemotherapeutics and PI3K/mTOR inhibitors. Thus,
small-moleculeinhibitorsofPI3K/Akt/mTORsignalingrepresent
a promising approach to engage the mitochondrial pathway of
apoptosis in order to overcome drug resistance.
CONCLUSIONS
Mitochondrial apoptosis represents a key signal transduction
pathway that is critically involved in the regulation of chemosen-
sitivity of human cancers. Targeted modulation of mitochondrial
outer membrane permeabilization, for example using small-
molecule inhibitors, opens new perspectives to lower the thresh-
old for cell death induction and to overcome at least some forms
of drug resistance. This calls for further development of com-
bination treatment strategies, aiming at lowering the threshold
for mitochondria-meditated cell death induction together with
additional cytotoxic strategies.
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